The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
Open accessAbstract
BACKGROUND: SGLT2 inhibitors are strongly recommended in guidelines to treat patients with heart failure with reduced ejection fraction, but their clinical benefits at higher ejection fractions are less well established. Two large-scale trials, DELIVER and EMPEROR-Preserved, in heart failure with mildly reduced or preserved ejection fraction have been done, providing power to examine therapeutic effects on cardiovascular mortality and in patient subgroups when combined with the earlier trials in reduced ejection fraction. METHODS: We did a prespecified meta-analysis of DELIVER and EMPEROR-Preserved, and subsequently included trials that enrolled patients with reduced ejection fraction (DAPA-HF and EMPEROR-Reduced) and those admitted to hospital with worsening heart failure, irrespective of ejection fraction (SOLOIST-WHF). Using trial-level data with harmonised endpoint definitions, we did a fixed-effects meta-analysis to estimate the effect of SGLT2 inhibitors on various clinical endpoints in heart failure The primary endpoint for this meta-analysis was time from randomisation to the occurrence of the composite of cardiovascular death or hospitalisation for heart failure. We assessed heterogeneity in treatment effects for the primary endpoint across subgroups of interest. This study is registered with PROSPERO, CRD42022327527. FINDINGS: Among 12 251 participants from DELIVER and EMPEROR-Preserved, SGLT2 inhibitors reduced composite cardiovascular death or first hospitalisation for heart failure (hazard ratio 0·80 [95% CI 0·73-0·87]) with consistent reductions in both components: cardiovascular death (0·88 [0·77-1·00]) and first hospitalisation for heart failure (0·74 [0·67-0·83]). In the broader context of the five trials of 21 947 participants, SGLT2 inhibitors reduced the risk of composite cardiovascular death or hospitalisation for heart failure (0·77 [0·72-0·82]), cardiovascular death (0·87 [0·79-0·95]), first hospitalisation for heart failure (0·72 [0·67-0·78]), and all-cause mortality (0·92 [0·86-0·99]). These treatment effects for each of the studied endpoints were consistently observed in both the trials of heart failure with mildly reduced or preserved ejection fraction and across all five trials. Treatment effects on the primary endpoint were generally consistent across the 14 subgroups examined, including ejection fraction. INTERPRETATION: SGLT2 inhibitors reduced the risk of cardiovascular death and hospitalisations for heart failure in a broad range of patients with heart failure, supporting their role as a foundational therapy for heart failure, irrespective of ejection fraction or care setting. FUNDING: None.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These drug classes are recommended as glucose-lowering therapy for individuals with cardiovascular disease or risk factors6,7 on the basis of randomized clinical trial evidence demonstrating a reduction in cardiovascular events (SGLT2is and GLP-1RAs)14,15,16 or suggesting cardiovascular benefit (metformin and pioglitazone).17,18”
From Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis (2025) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Large placebo-controlled trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of cardiovascular disease, and particularly hospitalisation for heart failure, in patients with type 2 diabetes at high risk of atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease.”
From Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials (2022) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“a large meta-analysis (308) including the EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, and the Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) trials included 21,947 individuals and demonstrated reduced risk for the composite of cardiovascular death or hospitalization for heart failure, cardiovascular death,”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [308]
The cited source says what the claim attributes to it.
In the citing paper
“A large meta-analysis (297) including the EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, and SOLOIST-WHF trials included 21,947 individuals and demonstrated reduced risk for the composite of cardiovascular death or hospitalization for heart failure, cardiovascular death, first hospitalization for heart failure, and all-cause mortality.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [297]
The cited source says what the claim attributes to it.
In the citing paper
“The findings on the studied end points were consistent in both trials of heart failure with mildly reduced or preserved ejection fraction and in all five trials combined.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [297]
In the citing paper
“Over the past decade, several large RCTs failed to achieve statistical significance with regard to effects on the primary outcomes in patients with HFpEF including: PEP-CHF (perindopril), CHARM-Preserved (candesartan), I-PRESERVE (irbesartan), TOPCAT (spironolactone), DIG Ancillary Trial (digoxin), and PARAGON-HF (sacubitril/valsartan). 477,[534][535][536][537][538]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [535]
In the citing paper
“There is good evidence to support the use of SGLT2 inhibitors as a foundational therapy to prevent cardiovascular death or hospitalisation for heart failure in patients with heart failure, irrespective of ejection fraction or history of previous diabetes.1, 2, 3, 4, 5”
In the citing paper
“A large recent meta-analysis (227) including data from EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, and Effect of Sotagli fl ozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOISTWHF) included 21,947 patients and demonstrated reduced risk for the composite of cardiovascular death or hospitalization for heart failure, cardiovascular death, fi r”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [227]
In the citing paper
“The fi ndings on the studied end points were consistent in both trials of heart failure with mildly reduced or preserved ejection fraction and in all fi ve trials combined.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [227]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citationDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206286 · Cited by 2,884
Self-citationSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Zannad, F., Ferreira, J. P., Pocock, S. J., Anker, S. D., Butler, J., Filippatos, G., Brueckmann, M., Ofstad, A. P., Pfarr, E., Jamal, W., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31824-9 · Cited by 1,408
McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.011 · Cited by 931
Self-citationSolomon, S. D., Anavekar, N. S., Skali, H., McMurray, J. J. V., Swedberg, K. B., Yusuf, S., Granger, C. B., Michelson, E. L., Wang, D., Pocock, S., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.561423 · Cited by 873
Self-citation
Research works printed but not linked: 1
- Zannad, 2020, SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials, Lancet, 396, 819, 10.1016/S0140-6736(20)31824-9 · DOI · Paper page
Cited by
Sorted by citations
Items 401–500 of 1,000
Fong, J. M. N., Sia, C., & See, K. C. (2025) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2025-012 · Cited by 5
Rosano, G. M. C., Teerlink, J. R., Kinugawa, K., Bayés‐Genís, A., Chioncel, O. D., Fang, J. C.-T., Greenberg, B., Ibrahim, N. E., Imamura, T., Inomata, T., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.03.014 · Cited by 9
Sen, S. (2023) · The American Journal of Managed Care · doi:10.37765/ajmc.2023.89415 · Cited by 6
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2166-6755 · Cited by 5
Islam, L., Jose, D., Alkhalifah, M. K., Blaibel, D., Chandrabalan, V., & Pappachan, J. M. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i3.463 · Cited by 6
Time trends and regional variation in utilization of antidiabetic medicines in China, 2015–2022
Zhang, J., Xu, S., Liu, X., Zhang, J., Hu, S., Liu, X., Yang, C., & Fang, Y. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15594 · Cited by 6
Inciardi, R. M., Merlo, M., Bellicini, M., Setti, M., Luca, A. D., Meo, N. D., Rondi, P., Pagnesi, M., Adamo, M., Lombardi, C., et al. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.04.009 · Cited by 6
Mapping the aetiological foundations of the heart failure spectrum using human geneticsPreprint
Henry, A., Mo, X., Finan, C., Chaffin, M. D., Speed, D., Issa, H. G., Denaxas, S., Ware, J. S., Zheng, S. L., Mälarstig, A., et al. (2023) · medRxiv · doi:10.1101/2023.10.01.23296379 · Cited by 6
Zhang, K., Kan, C., Han, F., Zhang, J., & Sun, X. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i2.137 · Cited by 6
Zhang, Z., Li, D., Zhao, J., Ma, H., Wang, F., & Hao, Q. (2025) · Alexandria Engineering Journal · doi:10.1016/j.aej.2025.04.066 · Cited by 5
Goodman, J. A., Schain, M., Stefano, G. D., Lupson, V. C., Horn, T., Hill, M., Manavaki, R., Fryer, T. D., Bumanlag-Amis, E., Jalaludeen, N., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-04559-3 · Cited by 5
Noninsulin Therapies in Management of Type 1 Diabetes
Saeed, Z. I., Ambalavanan, J., Rayan, M. N., Patadia, P., & Shah, V. N. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.06.027 · Cited by 5
Gries, J. J., Chen, B., Bansal, M. B., Rodríguez, M., Alqahtani, S. A., Brennan, P., Lang, C. C., Tang, W. H. W., Lazarus, J. V., & Krittanawong, C. (2025) · Communications Medicine · doi:10.1038/s43856-025-00951-2 · Cited by 6
Cardiovascular disease epidemiology and management in the elderly and very elderly
Galati, G., Андреевна, Г. О., Dacquino, G. M., Bravo, F. F., Genovese, L., & Pedretti, R. F. E. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf470 · Cited by 6
Bhandari, K., Qadri, M., Dhakal, R., Ghimire, S., Jora, G., Basyal, S., & Shah, S. K. (2025) · Cardiovascular Therapeutics · doi:10.1155/cdr/6649731 · Cited by 5
Self-citationZuin, M., Temporelli, P. L., Bilato, C., Corsini, A., Oliva, F. G., Savarese, G., & Caterina, R. D. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106615 · Cited by 5
Paolillo, S., Marzano, F., Bruzzese, D., Santo, M. D., Nardi, E., Asile, G., Cotticelli, C., Filardi, F. P., Fontanarosa, S., Smarrazzo, M., et al. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104366 · Cited by 5
2025 ESC/EACTS Guidelines for the management of valvular heart disease
Praz, F., Borger, M. A., Lanz, J., Cuartas, M. M., Abreu, A., Adamo, M., Marsan, N. A., Barili, F., Bonaros, N. E., Cosyns, B., et al. (2025) · European Heart Journal - Valvular and Structural Heart Disease · doi:10.1093/ehjvshd/xwag001 · Cited by 6
Chen, S., Hu, X., Wang, Q., Bakker, D., van der Made, I., Tebbens, A. M., Guan, Y., Lykidou, M., van Goor, F. K. J., Hollmann, M. W., et al. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156568 · Cited by 6
CVOT Summit Report 2025: advances along the cardiovascular–kidney–metabolic disease continuum
Schnell, O., Agarwal, A., Azizi, M., Ballwieser, D. A., Barnard-Kelly, K. D., Battelino, T., Ballwieser, D. A., Blüher, M., Bugianesi, E., Cebrián, A., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03140-0 · Cited by 5
Self-citationYang, E., & Rashid, H. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1349584 · Cited by 5
Renal Denervation in Heart Failure Treatment: Data for a Self-Fulfilling Prophecy
Dimitriadis, K. S., Iliakis, P., Pyrpyris, N., Tatakis, F., Fragoulis, C., Mantziaris, V., Plaitis, A., Beneki, E., Tsioufis, P., Hering, D., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226656 · Cited by 5
Ebrahimi, P., Soleimani, H., Mahalleh, M., Farisi, P., Taheri, M., Ramezani, P., Soltani, P., Nazari, R., Senobari, N., Mousavinezhad, S. M., et al. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01545-w · Cited by 5
Almeida, O. P. (2025) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000001001 · Cited by 6
Dutta, D., Nagendra, L., Kamrul-Hasan, A. B. M., & Mahajan, K. (2025) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2025.21.1.1 · Cited by 6
Screening for Undiagnosed Heart Failure: A Viewpoint
Ferreira, J. P., & Zannad, F. M. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.04.016 · Cited by 6
Scheen, A. J. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2527092 · Cited by 5
Neijenhuis, R. M. L., Regeer, M. V., Walker, N. L., Mertens, B. J. A., Hunter, A. L., Kiès, P., Swan, L., Vliegen, H. W., MacDonald, S. T., Zemrak, F., et al. (2025) · Open Heart · doi:10.1136/openhrt-2025-003445 · Cited by 6
Håkansson, E., Brunström, M., Norberg, H., Själander, S., & Lindmark, K. (2022) · Open Heart · doi:10.1136/openhrt-2022-002133 · Cited by 5
Chan, J. S. K., Perone, F., Bayatpoor, Y., Tse, G., & Harky, A. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2204188 · Cited by 6
Li, R., Dai, G., Guan, H., Gao, W., Ren, L., Wang, X., & Qu, H. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1143658 · Cited by 6
Kotit, S. (2023) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2023.14 · Cited by 6
Diévart, F., Darmon, P., Halimi, J., Hadjadj, S., Angoulvant, D., Prévost, G., Delanaye, P., & Boivin, J. (2023) · Néphrologie & Thérapeutique · doi:10.1684/ndt.2023.25 · Cited by 8
Arriola‐Montenegro, J., Beas, R., Cerna-Viacava, R., Chapoñan-Lavalle, A., Randich, K. H., Chambergo‐Michilot, D., Sanga, H. F., & Mutirangura, P. (2023) · World Journal of Cardiology · doi:10.4330/wjc.v15.i7.328 · Cited by 5
Heart Failure Without a Reduced Ejection Fraction
Kumar, S. (2023) · The American Journal of Managed Care · doi:10.37765/ajmc.2023.89417 · Cited by 5
Bai, L., Sun, Y., Si, J., Ding, Z., Zhang, X., Zhang, Y., Xia, Y., & Liu, Y. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1265269 · Cited by 5
Cortés, M., Lorenzo, Ó., Lumpuy‐Castillo, J., Martínez-Albaladejo, S., Urquía, M. T., Pello, A. M., Becerra, A. J. B., Orejas, M., Navas, M. Á., Macia, E., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12206698 · Cited by 5
Kar, D., El-Wazir, A., Nath, M., Breeze, P. R., Jetha, K. A., Strong, M., Chilcott, J. B., Davies, M. J., Lee, A. C., de Lusignan, S., et al. (2023) · BMJ Public Health · doi:10.1136/bmjph-2023-000172 · Cited by 5
Boutsikos, I., Beltsios, E. T., Schmack, B., Pantazopoulos, I. N., & Chatzis, D. (2023) · Heart International · doi:10.17925/hi.2023.17.2.12 · Cited by 5
2023 focused update of the 2021 ESC heart failure guidelines: Key messages for clinical practice
Tomasoni, D., Cannata, A. N., Adamo, M., & Metra, M. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14163 · Cited by 5
Heart failure with preserved ejection fraction: implications for anaesthesia
Shah, A. M., Sabharwal, N. K., & Day, J. R. (2024) · BJA Education · doi:10.1016/j.bjae.2024.02.003 · Cited by 5
The role and mechanism of dapagliflozin in Alzheimer disease: A review
Chen, P., Liang, L., Dai, Y., & Hui, S. (2024) · Medicine · doi:10.1097/md.0000000000039687 · Cited by 5
The Emerging Role of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure
Gitto, M., Villaschi, A., Federici, M., Condorelli, G., & Stefanini, G. G. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230217143324 · Cited by 6
Gorący, A., Rosik, J., Szostak, J., Szostak, B., Retfiński, S., Machaj, F., & Pawlik, A. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2240021 · Cited by 5
Albani, S., Zilio, F., Scicchitano, P., Musella, F., Ceriello, L., Marini, M., Gori, M., Khoury, G., D’Andrea, A., Campana, M., et al. (2023) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2023.09.013 · Cited by 5
The neurometabolic axis: A novel therapeutic target in heart failure
Chakraborty, P., Po, S. S., Scherlag, B. J., & Dasari, T. W. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122122 · Cited by 5
SEC Working Group for the 2023 update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and SEC Guidelines Committee (2023) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2023.10.009 · Cited by 5
Rates of diabetic ketoacidosis with empagliflozin use during hospitalization for acute heart failure
Huang, C., Lee, J. S., & Lee, M. S. (2024) · Journal of Hospital Medicine · doi:10.1002/jhm.13268 · Cited by 5
Do we need dedicated heart failure with preserved ejection fraction clinics?
Lam, C. S. P., & Ho, J. E. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad172 · Cited by 5
Self-citationSGLT2 inhibitors: a therapy for everybody but not for anything?
Villaschi, A., Cesani, N., & Chiarito, M. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad372 · Cited by 5
Bile acids for diabetic cardiomyopathy
Weissman, D., & Maack, C. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01032-9 · Cited by 5
Diallo, A., Carlos‐Bolumbu, M., Duc, P., & Galtier, F. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103506 · Cited by 4
Valério, C. M., Saraiva, J. F. K., Valente, F., van de Sande‐Lee, S., Rocha, V. Z., Rached, F. H., Drager, L. F., Halpern, B., Júnior, W. S. D. S., Trujilho, F. R., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01954-8 · Cited by 8
Yang, J., Hwang, Y., Ju, J., Han, S., An, J., & Shim, J. H. (2026) · Hepatology · doi:10.1097/hep.0000000000001695 · Cited by 5
Hacil, A., Antakly, Y., Lacour, A., David, J.-P., Khalifa, T., Piccoli, M., Clemencin, A., Assayag, P., Vidal, J., & Hanon, O. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.02.011 · Cited by 4
Vanicek, L. R., Fischer, A., Jurado, M. R., Tamiato, A., Procida‐Kowalski, T., Wilhelm, J., Hecker, D., Merten, M., Escher, F., Kattih, B., et al. (2025) · FEBS Letters · doi:10.1002/1873-3468.70057 · Cited by 4
Ma, H., Zhang, J., Meng, B., Wang, K., Li, Y., & Liang, N. (2025) · PLoS ONE · doi:10.1371/journal.pone.0322886 · Cited by 5
Bonanad-Lozano, C., García‐Blas, S., Amat-Santos, I. J., Manzanares, R. G., Sanchis, J. M., López‐Otero, D., y, L. N.-F., Gheorge, L., Sanz‐Sánchez, J., Baladrón, C., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.07.051 · Cited by 4
Bukanova-Berend, D., Campbell-James, T. A., & Vogel, J. (2025) · BMC Health Services Research · doi:10.1186/s12913-025-13687-5 · Cited by 4
Gama, F. D. S., Ferreira, M. A., Segretti, N., Damião, M. C. F. C. B., Guimarães, C. R. W., Mascarello, A., & de Azevedo, H. F. Z. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02225 · Cited by 4
Gallwitz, B., Aberle, J., Birkenfeld, A. L., KELLERER, M., Klein, H. H., Landgraf, R., Müller‐Wieland, D., Müssig, K., Nauck, M. A., Siegel, E. G., et al. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2592-7923 · Cited by 4
Association of SGLT2 inhibitors and new-onset dementia in non-diabetic patients with heart failure
Hacil, A., Piccoli, M., Antakly, Y., Guglieri, M., Lochon, L., Duneton, S., Hanon, O., & Fauchier, L. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag038 · Cited by 4
Mone, P., Ferrone, M., Spione, F., Christodoulakis, D., Melillo, F., Rainone, A., Ponticelli, D., Tesorio, T., Mauro, M. D., Marro, A., et al. (2026) · Cardiovascular Research · doi:10.1093/cvr/cvag065 · Cited by 4
Heart failure and tricuspid regurgitation: the role of SGLT2 inhibitors in improving outcomes
Loutati, R., Copeland, V., Elimeleh, S., Hochstein, D., Faierstein, K., Milwidsky, A., Ben-Zekry, S., Segev, A., Kuperstein, R., & Maor, E. (2026) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvag018 · Cited by 4
The changing landscape of drug clinical trials on cardiometabolic diseases in China, 2009–2021
Li, C., Hao, J., Zheng, Y., Wang, C., Yang, J., Wang, W., Zhang, K., Shao, C., Wen, H., Wang, J., et al. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01043-8 · Cited by 4
SGLT2-inhibitors: Should they be considered anti-remodeling drugs?
Fabris, E., Sinagra, G., & Anker, S. D. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.05.023 · Cited by 4
Xiong, T., Jia, Y., Tan, F., Long, X., Yuan, X., She, Q., & Du, J. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.149434 · Cited by 4
Lelonek, M., Pawlak, A., Straburzyńska‐Migaj, E., Nessler, J. M., & Rubiś, P. (2024) · Kardiologia Polska · doi:10.33963/v.phj.98878 · Cited by 7
Çöllüoğlu, T., Çelik, A., Ata, N., Ural, D., Şahin, A., Ülgü, M. M., Kanık, E. A., Birinci, Ş., & Yılmaz, M. B. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132109 · Cited by 4
Sodium-glucose cotransporter 2 inhibitors: mechanisms of cardiorenal protection: A review
Васильевна, Л. М. (2024) · Consilium Medicum · doi:10.26442/20751753.2024.4.202763 · Cited by 4
Bult, M. M., van de Ree, T. F., Wind, A. M., Hurley, K. M., & van de Ree, M. A. (2024) · Journal of Clinical Hypertension · doi:10.1111/jch.14867 · Cited by 4
Soares, R. R., Viggiani, L. F., Filho, J. M. R., & Joviano‐Santos, J. V. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.111229 · Cited by 5
Prognostic Impact of Statins in Heart Failure with Preserved Ejection Fraction
Ortega-Hernández, S., Sosa, S. G., Martel, A. C., Trullàs, J. C., Llàcer, P., Pérez-Silvestre, J., Arévalo‐Lorido, J. C., Casado, J., Formiga, F., Manzano, L., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195844 · Cited by 4
Secondary Mitral Regurgitation: Updated Review with Focus on Percutaneous Interventional Management
Vinayak, M., Prandi, F. R., Safi, L. M., Sharma, A., Tang, G. H. L., Lerakis, S., Kini, A. S., Sharma, S. K., Pinney, S., Lala, A., et al. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.06.018 · Cited by 4
Seidita, A., Mandreucci, F., Pistone, M., Calderone, S., Giuliano, A., Chiavetta, M., Giannitrapani, L., Citarrella, R., Soresi, M., Licata, A., et al. (2024) · Italian Journal of Medicine · doi:10.4081/itjm.2024.1829 · Cited by 4
Janić, M., Janež, A., Šabović, M., El‐Tanani, M., Rangraze, I. R., Rizzo, M., & Lunder, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226860 · Cited by 7
Management of Pediatric Heart Failure
Dipchand, A. I. (2024) · Korean Circulation Journal · doi:10.4070/kcj.2024.0320 · Cited by 4
Ghukasyan, H., Navalha, D. D. P., Romero, I. P., Wolwacz, M. V. P., Ghahramanyan, A., Ngan, C. W. T., de Melo, M. H. S. T., Dagostin, C. S., & Quirós, L. G.-L. (2025) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2024.12.005 · Cited by 4
Cardiovascular Outcomes With Antidiabetic Drugs in People With Type 2 Diabetes and a Prior Stroke
Bae, J. H., Choi, J., Kim, N. H., & Kim, S. G. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.08.015 · Cited by 5
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2025) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2025.05.010 · Cited by 4
Forsyth, F., Deaton, C., Kalra, P. R., Green, M., Harrison, M., Tavares, S., Dirksen, A., Kuhn, I. L., Farquharson, B., & Austin, R. C. (2025) · European Journal of Cardiovascular Nursing · doi:10.1093/eurjcn/zvaf143 · Cited by 4
SGLT2 inhibitors as the bedrock of therapy for heart failure
Tuttle, K. R., & Rangaswami, J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01584-7 · Cited by 4
Patoulias, D., Michailidis, T., Dimosiari, A., Kassimis, G., & Fragakis, N. (2022) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2022.200161 · Cited by 4
Chen, H., Meng, R., Yang, Y., & Yu, T.-H. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2182290 · Cited by 4
Starr, J. A., & Pinner, N. A. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231189508 · Cited by 5
Lu, H., Shang, P., & Zhou, D. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1155210 · Cited by 4
Nogueira, A. C. C., Barreto, J., Moura, F. A., Luchiari, B., Abuhab, A., Bonilha, I., Nadruz, W., Gaziano, J. M., Gaziano, T. A., de Carvalho, L. S. F., et al. (2023) · Health Economics Review · doi:10.1186/s13561-023-00466-3 · Cited by 4
Odutayo, A., Zinman, B., Wanner, C., Zwiener, I., Lund, S. S., Hantel, S., FITCHETT, D. H., & Udell, J. A. (2024) · CJC Open · doi:10.1016/j.cjco.2024.01.013 · Cited by 4
Dawson, L. P., Carrington, M. J., Haregu, T., Nanayakkara, S., Jennings, G., Dart, A. M., Stub, D. A., Inouye, M., & Kaye, D. M. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.034254 · Cited by 4
Philip, M. A., Webb, C. M., Chakraborty, T., & Collins, P. D. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14979 · Cited by 4
SGLT2 Inhibitors: Emerging Opportunities for the Treatment of Myocardial Infarction
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7568-2_4 · Cited by 4
A welcome ‘failure’ of gliflozins: blood pressure reduction in heart failure
Docherty, K. F., & Jhund, P. S. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac712 · Cited by 4
Self-citationHoshida, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030802 · Cited by 4
López‐Candales, A., Sawalha, K., Drees, B. M., & Norgard, N. B. (2023) · Postgraduate Medicine · doi:10.1080/00325481.2023.2181537 · Cited by 4
SGLT2 inhibitors in CKD and HFpEF: two new large trials and two new meta-analyses
Mayne, K. J., Preiss, D., & Herrington, W. G. (2023) · British Journal of Cardiology · doi:10.5837/bjc.2023.003 · Cited by 4
Precision geromedicine: Science meets clinical practice
Chen, L. (2025) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2025.106057 · Cited by 4
Glucose-Lowering Agents Developed in the Last Two Decades and Their Perioperative Implications
Goudra, B., Merli, G. J., & Green, M. S. (2024) · Pharmaceuticals · doi:10.3390/ph18010004 · Cited by 3
Combination of SGLT2 Inhibitors and Loop Diuretics in the Treatment of Heart Failure
Murakami, Y., Kiuchi, S., Hisatake, S., & Ikeda, T. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15030099 · Cited by 3
Endothelin receptor antagonists for diabetic kidney disease: back to the future?
Anyfanti, P., Theodorakopoulou, M. P., Iatridi, F., & Sarafidis, P. A. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2500294 · Cited by 4
Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure Patients
Gautier, P., Elbaz, M., Bezin, J., Delmas, C., Cherbi, M., Bouisset, F., Vindis, C., Renoux, A., Lafaurie, M., & Montastruc, F. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.02.017 · Cited by 3
Metadata
- Authors
- Vaduganathan, M., Docherty, K. F., Claggett, B. L., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., Shah, S. J., Desai, A. S., McMurray, J. J. V., & Solomon, S. D.
- Affiliations
- Brigham and Women's Hospital (US)
- British Heart Foundation (GB)
- Duke Medical Center (US)
- Yale University (US)
- University of Missouri–Kansas City (US)
- National University of Singapore (SG)
- Northwestern University (US)
- Corresponding author
- Solomon, Scott D
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2022-09
- Volume
- 400
- Issue
- 10354
- Pages
- 757-767
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4293353625
- Cited by
- 996
- References
- 24
- Citations by year
- 2026: 215 · 2025: 203 · 2024: 279 · 2023: 257 · 2022: 42
- FWCI
- 39.76
- Type
- journal article
- Language
- en
- Update notices
- erratum (2023-01-14)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion, public-domain)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (acceptedVersion, public-domain)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, public-domain)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Amgen
- Eli Lilly and Company (NCT03057951)
- Pfizer
- AstraZeneca
- Sanofi
- National Institutes of Health
- Defense Acquisition Program Administration
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- SGLT2 inhibitors, heart failure, heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, cardiovascular mortality, heart failure hospitalization, all-cause mortality, subgroup analysis, DAPA-HF, EMPEROR-Preserved, EMPEROR-Reduced, cardiovascular risk stratification, treatment effect heterogeneity
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Heart Failure, Hospitalization, Humans, Stroke Volume, Randomized Controlled Trials as Topic, Ventricular Function, Left, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
